Advertisement

Feverfew

  • Richard L. Kingston
Part of the Forensic Science and Medicine book series (FSM)

Abstract

Although feverfew has been demonstrated to provide therapeutic benefit to isolated patient groups and at varying dosage levels, its clinical effectiveness has not been consistently reported. A variety of caveats associated with study design, identification or concentration of appropriate substance, or duration of evaluation from previous clinical studies complicate the assessment of the overall benefit of the herb. Despite inconsistent reports of effectiveness, the favorable safety profile and low risk of use suggest a positive risk benefit for patients looking for migraine prophylaxis treatment alternatives.

Key Words

Tanacetum partheium migraine parthenolide oral ulceration sesquiterpene lactones 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous, ed. Feverfew. In:The Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, 1994.Google Scholar
  2. 2.
    Tyler VE, ed. The Honest Herbal, 3rd edition. Binghamton: Pharmaceutical Products Press, 1993.Google Scholar
  3. 3.
    Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep 1995;12:271–276.PubMedCrossRefGoogle Scholar
  4. 4.
    United States Pharmacopeial Convention (USP). Feverfew. Botanical Monograph Series. Rockville: United States Pharmacopeial Convention, 1998.Google Scholar
  5. 5.
    Heptinstall S, Awang DVC, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium [L.] schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 1992;44:391–395.PubMedGoogle Scholar
  6. 6.
    Tyler VE, ed. Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton: Pharmaceuticals Products Press, 1994.Google Scholar
  7. 7.
    Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985;291:569–573.Google Scholar
  8. 8.
    Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997; 11:508–511.CrossRefGoogle Scholar
  9. 9.
    Murphy JJ, Heptinstall S, Mitchell JRA. Randomized, double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189–192.PubMedCrossRefGoogle Scholar
  10. 10.
    Groenewegen WA, Heptinstall S. Amounts of feverfew in commercial perparations of the herb. Lancet 1986;1:44–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Collier HOJ, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 1980;2:922–923.PubMedCrossRefGoogle Scholar
  12. 12.
    Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 1982;8:653–660.PubMedGoogle Scholar
  13. 13.
    Maries RJ, Kaminski J, Arnason JT. A bioassay for the inhibition of serotonin release from bovine platelets. J Nat Prod 1992;55:1044–1056.CrossRefGoogle Scholar
  14. 14.
    Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro. J Pharm Pharmacol 1990;42:553–557.PubMedGoogle Scholar
  15. 15.
    Barsby RWJ, Salan U, Knight DW, Hoult JRS. Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993;59:20–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Hay AJB, Hamburger M, Hostettmann K, Hoult JRS. Toxic inhibition of smooth muscle contractility by plant-derived sesquiterpenes caused by their chemically reactive a;-methylenebutyrolactone functions. Br J Pharmacol 1994; 112:9–12.PubMedGoogle Scholar
  17. 17.
    Barsby RWJ, Knight DW, McFadzean I. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells. J Pharm Pharmacol 1993;45:641–645.PubMedGoogle Scholar
  18. 18.
    DeWeerdt CJ, Bootsma HPR, Hendriks H. Herbal medicine in migraine prevention: randomized, double-blind, placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225–230.Google Scholar
  19. 19.
    Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598–1599.PubMedCrossRefGoogle Scholar
  20. 20.
    Pfaffenrath V, Diener HC, Fischeer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxix — a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22(7):523–532.PubMedCrossRefGoogle Scholar
  21. 21.
    Maizels M, Blumenfeld A, Burchette MS. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44(sn9):885–890.PubMedCrossRefGoogle Scholar
  22. 22.
    Curry EA III, Murray DJ, Yoder C, Fife K, Armstrong V. Phase I dose excalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22(3):299–305.PubMedCrossRefGoogle Scholar
  23. 23.
    O’Neill LAJ, Barrett ML, Lewis GP. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 1987;23:81–83.PubMedGoogle Scholar
  24. 24.
    Lee K, Huang E, Piantadosi C, Pagano JS, Geissman TA. Cytotoxicity of sesquiterpene lactones. Cancer Res 1971;31:1649–1654.PubMedGoogle Scholar
  25. 25.
    Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis 1989;48:547–549.PubMedCrossRefGoogle Scholar
  26. 26.
    Anderson D, Jenkinson PC, Dewdney RS, Blowere SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and age matched nonusers. Hum Toxicol 1988;7:145–152.PubMedCrossRefGoogle Scholar
  27. 27.
    Benner MH, Lee HJ. Anaphylactic reaction to chamomile tea. J Allergy Clin Immunol 1973;52:307–308.PubMedCrossRefGoogle Scholar
  28. 28.
    Awang DVC. Feverfew fever. A headache for the consumer. HerbalGram 1993;29:34–36, 66.Google Scholar
  29. 29.
    Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;2:776.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Richard L. Kingston

There are no affiliations available

Personalised recommendations